Nodthera Announces Presentation At The 44Th Annual J.P. Morgan Healthcare Conference

(MENAFN- GlobeNewsWire - Nasdaq) BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today announced that Chris Guiffre, J.D., M.B.A., Chief Financial Officer of NodThera, will present at the 44^th Annual J.P. Morgan Healthcare Conference being held January 12-15, 2026, in San Francisco, CA.

Details of the presentation are as follows:

44^th Annual J.P. Morgan Healthcare Conference

Date: Wednesday, January 14, 2026

Time: 8:00 AM PT / 11:00 AM ET

Location: The Westin St. Francis Hotel, San Francisco, CA

About NLRP3

NLRP3 activation mediates the release of proinflammatory cytokines, including IL-6, IL-18 and IL-1β, driving chronic inflammation in cardiometabolic, neurological and other diseases. NLRP3 Inhibition offers an alternative approach to therapeutic blockade of individual cytokines IL-6, IL-18 or IL-1β.

About NodThera

NodThera, a US and UK based biotech developing best-in-class NLRP3 inhibitors, is pioneering a paradigm shift in the treatment of diseases driven by chronic inflammation. NodThera has led the science for a decade; and has built an advanced pipeline of multiple clinical-stage small-molecule NLRP3 inhibitors. Compelling first-in-class clinical data, including in patients with cardiometabolic and neurological diseases, is fuelling rapid clinical development towards multiple approvals.

NodThera is backed by top-tier investors including 5AM Ventures, Blue Owl Capital, Epidarex Capital, F-Prime Capital, Novo Holdings, Sanofi Ventures and Sofinnova Partners.

NodThera is headquartered in Boston, Massachusetts, with an R&D base in the UK. Learn more at or follow the Company on LinkedIn.

Investors and Media
Argot Partners
...

MENAFN06012026004107003653ID1110562054